PCV15, a pneumococcal conjugate vaccine, for the prevention of invasive pneumococcal disease in infants and children

References

• De Schutter I, Vergison A, Tuerlinckx D, et al. Pneumococcal aetiology and serotype distribution in paediatric community-acquired pneumonia. PLoS One. 2014;9(2):e89013. doi: 10.1371/journal.pone.0089013
   PubMed Web of Science ®Google Scholar
• Mackenzie GA, Hill PC, Gambia Pneumococcal Surveillance Group. Impact of the introduction of pneumococcal conjugate vaccination on invasive pneumococcal disease and pneumonia in the Gambia: 10 years of population-based surveillance. Lancet Infect Dis. 2021 Sep;21(9):1293–1302.
   PubMed Web of Science ®Google Scholar
• Jain S, Williams DJ, Arnold SR, et al. Community-acquired pneumonia requiring hospitalization among U.S. children. N Engl J Med. 2015 Feb 26;372(9):835–845. doi: 10.1056/NEJMoa1405870
   PubMed Web of Science ®Google Scholar
• Marom T, Alvarez-Fernandez PE, Jennings K, et al. Acute bacterial sinusitis complicating viral upper respiratory tract infection in young children. Pediatr Infect Dis J. 2014 Aug;33(8):803–808.
   PubMed Web of Science ®Google Scholar
• Ngo CC, Massa HM, Thornton RB, et al. Predominant bacteria detected from the middle ear fluid of children experiencing otitis media: a systematic review. PLoS One. 2016;11(3):e0150949. doi: 10.1371/journal.pone.0150949
   PubMed Web of Science ®Google Scholar
• Wahl B, O’Brien KL, Greenbaum A, et al. Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000-15. Lancet Glob Health. 2018 Jul;6(7):e744–e757.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Active bacterial core surveillance (ABCs) report. Emerging infections program network. Streptococcus pneumonia. 2018 [cited 2023 Mar 29]. Available from: http://www.cdc.gov/abcs/reports-finds/surv-reports.html
   Google Scholar
• Fenoll A, Jado I, Vicioso D, et al. Streptococcus pneumoniae in children in Spain: 1990-1999. Acta Paediatr Suppl. 2000 Dec;89(435):44–50.
   PubMedGoogle Scholar
• Hausdorff WP, Bryant J, Kloek C, et al. The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II. Clin Infect Dis. 2000 Jan;30(1):122–140.
   PubMed Web of Science ®Google Scholar
• Musher DM, Anderson R, Feldman C. The remarkable history of pneumococcal vaccination: an ongoing challenge. Pneumonia. 2022 Sep 25;14(1):5. doi: 10.1186/s41479-022-00097-y
   Web of Science ®Google Scholar
• Anderson P, Pichichero ME, Insel RA. Immunogens consisting of oligosaccharides from the capsule of Haemophilus influenzae type b coupled to diphtheria toxoid or the toxin protein CRM197. J Clin Invest. 1985 Jul;76(1):52–59. doi: 10.1172/JCI111976
   PubMed Web of Science ®Google Scholar
• American Academy of Pediatrics. Committee on Infectious Diseases. Policy statement: recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis. Pediatrics. 2000 Aug;106(2 Pt 1):362–366. doi: 10.1542/peds.106.2.362
   PubMed Web of Science ®Google Scholar
• Dagan R, Givon-Lavi N, Fraser D, et al. Serum serotype-specific pneumococcal anticapsular immunoglobulin g concentrations after immunization with a 9-valent conjugate pneumococcal vaccine correlate with nasopharyngeal acquisition of pneumococcus. J Infect Dis. 2005 Aug 1;192(3):367–376. doi: 10.1086/431679
   PubMed Web of Science ®Google Scholar
• Jokinen JT, Ahman H, Kilpi TM, et al. Concentration of antipneumococcal antibodies as a serological correlate of protection: an application to acute otitis media. J Infect Dis. 2004 Aug 1;190(3):545–550. doi: 10.1086/422531
   PubMed Web of Science ®Google Scholar
• Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010 Jan 1;201(1):32–41. doi: 10.1086/648593
   PubMed Web of Science ®Google Scholar
• Simonsen L, Taylor RJ, Young-Xu Y, et al. Impact of pneumococcal conjugate vaccination of infants on pneumonia and influenza hospitalization and mortality in all age groups in the United States. MBio. 2011 Jan 25;2(1):e00309–10. doi: 10.1128/mBio.00309-10
   PubMed Web of Science ®Google Scholar
• Agency EM Synflorix, pneumococcal polysaccharide conjugate vaccine (adsorbed): summary of product characteristics. [cited 2023 Apr 21]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000973/WC500054346.pdf
   Google Scholar
• Centers for Disease Control and Prevention. Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children - Advisory Committee on immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep. 2010 Mar 12;59(9):258–261.
   PubMedGoogle Scholar
• World Health Organization. Prequalified vaccines. Pneumosil®. 2019 [cited 2023 Jun]. Available from: https://extranet.who.int/pqweb/content/pneumosil%C2%AE
   Google Scholar
• Kobayashi M, Farrar JL, Gierke R, et al. Use of 15-valent pneumococcal conjugate vaccine and 20-valent pneumococcal conjugate vaccine among U.S. Adults: Updated recommendations of the advisory committee on immunization practices - United States, 2022. MMWR Morb Mortal Wkly Rep. 2022 Jan 28;71(4):109–117. doi: 10.15585/mmwr.mm7104a1
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Vaccines. Prevnar 20. [cited 2023 Jun]. Available from: https://www.fda.gov/vaccines-blood-biologics/vaccines/prevnar-20
   Google Scholar
• Baxter R, Aukes L, Pelton SI, et al. Impact of the 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease After Introduction Into Routine Pediatric Use. J Pediatric Infect Dis Soc. 2021 Mar 26;10(2):141–150. doi: 10.1093/jpids/piaa035
   PubMed Web of Science ®Google Scholar
• Berman-Rosa M, O’Donnell S, Barker M, et al. Efficacy and effectiveness of the PCV-10 and PCV-13 vaccines against invasive pneumococcal disease. Pediatrics. 2020 Apr;145(4). doi: 10.1542/peds.2019-0377
   PubMed Web of Science ®Google Scholar
• Ciruela P, Izquierdo C, Broner S, et al. The changing epidemiology of invasive pneumococcal disease after PCV13 vaccination in a country with intermediate vaccination coverage. Vaccine. 2018 Nov 29;36(50):7744–7752. doi: 10.1016/j.vaccine.2018.05.026
   PubMed Web of Science ®Google Scholar
• de Miguel S, Domenech M, Gonzalez-Camacho F, et al. Nationwide trends of invasive pneumococcal disease in Spain from 2009 Through 2019 in children and adults during the pneumococcal conjugate vaccine era. Clin Infect Dis. 2021 Dec 6;73(11):e3778–e3787. doi: 10.1093/cid/ciaa1483
   PubMed Web of Science ®Google Scholar
• Naucler P, Galanis I, Morfeldt E, et al. Comparison of the Impact of Pneumococcal Conjugate Vaccine 10 or Pneumococcal Conjugate Vaccine 13 on Invasive Pneumococcal Disease in Equivalent Populations. Clin Infect Dis. 2017 Nov 13;65(11):1780–1789. doi: 10.1093/cid/cix685
   PubMed Web of Science ®Google Scholar
• Rinta-Kokko H, Palmu AA, Auranen K, et al. Long-term impact of 10-valent pneumococcal conjugate vaccination on invasive pneumococcal disease among children in Finland. Vaccine. 2018 Apr 5;36(15):1934–1940. doi: 10.1016/j.vaccine.2018.03.001
   PubMed Web of Science ®Google Scholar
• Savulescu C, Krizova P, Lepoutre A, et al. Effect of high-valency pneumococcal conjugate vaccines on invasive pneumococcal disease in children in SpIDnet countries: an observational multicentre study. Lancet Respir Med. 2017 Aug;5(8):648–656.
   PubMed Web of Science ®Google Scholar
• Waight PA, Andrews NJ, Ladhani SN, et al. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Lancet Infect Dis. 2015 May;15(5):535–543.
   PubMed Web of Science ®Google Scholar
• Ben-Shimol S, Givon-Lavi N, Leibovitz E, et al. Impact of widespread introduction of pneumococcal conjugate vaccines on pneumococcal and nonpneumococcal otitis media. Clin Infect Dis. 2016 Sep 1;63(5):611–618. doi: 10.1093/cid/ciw347
   PubMed Web of Science ®Google Scholar
• de Oliveira LH, Shioda K, Valenzuela MT, et al. Declines in pneumonia mortality following the introduction of pneumococcal conjugate vaccines in Latin American and Caribbean countries. Clin Infect Dis. 2021 Jul 15;73(2):306–313. doi: 10.1093/cid/ciaa614
   PubMed Web of Science ®Google Scholar
• Gonullu E, Soysal A, Yildiz I, et al. Impact of the 13-valent pneumococcal conjugate vaccine on the incidences of community-acquired pneumonia and pneumonia-related hospitalizations in children </=5 years after its implementation into the national immunization program of turkey. Hum Vaccin Immunother. 2020 Oct 2;16(10):2504–2508. doi: 10.1080/21645515.2020.1727212
   PubMed Web of Science ®Google Scholar
• Mackenzie GA, Hill PC, Sahito SM, et al. Impact of the introduction of pneumococcal conjugate vaccination on pneumonia in the Gambia: population-based surveillance and case-control studies. Lancet Infect Dis. 2017 Sep;17(9):965–973.
   PubMed Web of Science ®Google Scholar
• Olarte L, Barson WJ, Barson RM, et al. Pneumococcal Pneumonia Requiring Hospitalization in US Children in the 13-Valent Pneumococcal Conjugate Vaccine Era. Clin Infect Dis. 2017 Jun 15;64(12):1699–1704. doi: 10.1093/cid/cix115
   PubMed Web of Science ®Google Scholar
• Reyburn R, Tuivaga E, Nguyen CD, et al. Effect of ten-valent pneumococcal conjugate vaccine introduction on pneumonia hospital admissions in Fiji: a time-series analysis. Lancet Glob Health. 2021 Jan;9(1):e91–e98.
   PubMed Web of Science ®Google Scholar
• Ben-Shimol S, Greenberg D, Givon-Lavi N, et al. Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: an active prospective nationwide surveillance. Vaccine. 2014 Jun 5;32(27):3452–3459. doi: 10.1016/j.vaccine.2014.03.065
   PubMed Web of Science ®Google Scholar
• Gisselsson-Solen M. Trends in Otitis Media Incidence After Conjugate Pneumococcal Vaccination: A National Observational Study. Pediatr Infect Dis J. 2017 Nov;36(11):1027–1031. doi: 10.1097/INF.0000000000001654
   PubMed Web of Science ®Google Scholar
• Rosenblut A, Rosenblut M, Garcia K, et al. Frequency of acute otitis media in children under 24 months of age before and after the introduction of the 10-valent pneumococcal conjugate vaccine into the national immunization program in Chile. Pediatr Infect Dis J. 2018 Feb;37(2):132–134.
   PubMed Web of Science ®Google Scholar
• Sartori AL, Minamisava R, Bierrenbach AL, et al. Reduction in all-cause otitis media-related outpatient visits in children after PCV10 introduction in Brazil. PLoS One. 2017;12(6):e0179222. doi: 10.1371/journal.pone.0179222
   PubMed Web of Science ®Google Scholar
• Suaya JA, Gessner BD, Fung S, et al. Acute otitis media, antimicrobial prescriptions, and medical expenses among children in the United States during 2011-2016. Vaccine. 2018 Nov 26;36(49):7479–7486. doi: 10.1016/j.vaccine.2018.10.060
   PubMed Web of Science ®Google Scholar
• Chang B, Akeda H, Nakamura Y, et al. Impact of thirteen-valent pneumococcal conjugate vaccine on nasopharyngeal carriage in healthy children under 24 months in Okinawa, Japan. J Infect Chemother. 2020 May;26(5):465–470.
   PubMed Web of Science ®Google Scholar
• Davis SM, Deloria-Knoll M, Kassa HT, et al. Impact of pneumococcal conjugate vaccines on nasopharyngeal carriage and invasive disease among unvaccinated people: review of evidence on indirect effects. Vaccine. 2013 Dec 17;32(1):133–145. doi: 10.1016/j.vaccine.2013.05.005
   PubMed Web of Science ®Google Scholar
• Felix S, Handem S, Nunes S, et al. Impact of private use of the 13-valent pneumococcal conjugate vaccine (PCV13) on pneumococcal carriage among Portuguese children living in urban and rural regions. Vaccine. 2021 Jul 22;39(32):4524–4533. doi: 10.1016/j.vaccine.2021.06.035
   PubMed Web of Science ®Google Scholar
• Lovlie A, Vestrheim DF, Aaberge IS, et al. Changes in pneumococcal carriage prevalence and factors associated with carriage in Norwegian children, four years after introduction of PCV13. BMC Infect Dis. 2020 Jan 10;20(1):29. doi: 10.1186/s12879-019-4754-0
   PubMed Web of Science ®Google Scholar
• Palmu AA, Toropainen M, Kaijalainen T, et al. Direct and indirect effectiveness of the 10-valent pneumococcal conjugate vaccine against carriage in a cluster randomized trial. Pediatr Infect Dis J. 2017 Dec;36(12):1193–1200.
   PubMed Web of Science ®Google Scholar
• Dagan R. Relationship between immune response to pneumococcal conjugate vaccines in infants and indirect protection after vaccine implementation. Expert Rev Vaccines. 2019 Jun;18(6):641–661. doi: 10.1080/14760584.2019.1627207
   PubMed Web of Science ®Google Scholar
• Andrade AL, Afonso ET, Minamisava R, et al. Direct and indirect impact of 10-valent pneumococcal conjugate vaccine introduction on pneumonia hospitalizations and economic burden in all age-groups in Brazil: a time-series analysis. PLoS One. 2017;12(9):e0184204. doi: 10.1371/journal.pone.0184204
   PubMed Web of Science ®Google Scholar
• Izu A, Solomon F, Nzenze SA, et al. Pneumococcal conjugate vaccines and hospitalization of children for pneumonia: a time-series analysis, South Africa, 2006-2014. Bull World Health Organ. 2017 Sep 1;95(9):618–628. doi: 10.2471/BLT.16.187849
   PubMed Web of Science ®Google Scholar
• Lopez EL, Glatstein E, Ezcurra GC, et al. Rapid Decrease in Rates of Hospitalization Resulting From Invasive Pneumococcal Disease and Community-Acquired Pneumonia in Children Aged <60 Months After 13-Valent Pneumococcal Conjugate Vaccine Introduction in Argentina. J Pediatric Infect Dis Soc. 2018 Feb 19;7(1):30–35. doi: 10.1093/jpids/piw089
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Global pneumococcal disease and vaccination. 2022 [cited 2023 May 1]. Available from: https://www.cdc.gov/pneumococcal/global.html
   Google Scholar
• Balsells E, Guillot L, Nair H, et al. Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: a systematic review and meta-analysis. PLoS One. 2017;12(5):e0177113. doi: 10.1371/journal.pone.0177113
   PubMed Web of Science ®Google Scholar
• Gagetti P, Lo SW, Hawkins PA, et al. Population genetic structure, serotype distribution and antibiotic resistance of Streptococcus pneumoniae causing invasive disease in children in Argentina. Microb Genom. 2021 Sep;7(9). doi: 10.1099/mgen.0.000636
   PubMed Web of Science ®Google Scholar
• Garcia Quesada M, Yang Y, Bennett JC, et al. Serotype distribution of remaining pneumococcal meningitis in the mature PCV10/13 period: findings from the PSERENADE project. Microorganisms. 2021 Apr 1;9(4). doi: 10.3390/microorganisms9040738
   Web of Science ®Google Scholar
• Peckeu L, van der Ende A, de Melker HE, et al. Impact and effectiveness of the 10-valent pneumococcal conjugate vaccine on invasive pneumococcal disease among children under 5 years of age in the Netherlands. Vaccine. 2021 Jan 8;39(2):431–437. doi: 10.1016/j.vaccine.2020.11.018
   PubMed Web of Science ®Google Scholar
• Wijayasri S, Hillier K, Lim GH, et al. The shifting epidemiology and serotype distribution of invasive pneumococcal disease in Ontario, Canada, 2007-2017. PLoS One. 2019;14(12):e0226353. doi: 10.1371/journal.pone.0226353
   PubMed Web of Science ®Google Scholar
• Harboe ZB, Dalby T, Weinberger DM, et al. Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality. Clin Infect Dis. 2014 Oct 15;59(8):1066–1073. doi: 10.1093/cid/ciu524
   PubMed Web of Science ®Google Scholar
• Lapidot R, Shea KM, Yildirim I, et al. Characteristics of serotype 3 invasive pneumococcal disease before and after universal childhood immunization with PCV13 in Massachusetts. Pathogens. 2020 May 21;9(5). doi: 10.3390/pathogens9050396
   PubMed Web of Science ®Google Scholar
• Reslan L, Youssef N, Boutros CF, et al. The impact of vaccination on the burden of invasive pneumococcal disease from a nationwide surveillance program in Lebanon: an unexpected increase in mortality driven by non-vaccine serotypes. Expert Rev Vaccines. 2022 Dec;21(12):1905–1921.
   PubMed Web of Science ®Google Scholar
• Grant LR, Slack MPE, Theilacker C, et al. Distribution of serotypes causing invasive pneumococcal disease in children from high-Income countries and the Impact of pediatric pneumococcal vaccination. Clin Infect Dis. 2023 Feb 8;76(3):e1062–e1070. doi: 10.1093/cid/ciac475
   PubMed Web of Science ®Google Scholar
• Bertran M, Amin-Chowdhury Z, Sheppard CL, et al. Increased Incidence of Invasive Pneumococcal Disease among Children after COVID-19 Pandemic, England. Emerg Infect Dis. 2022 Aug;28(8):1669–1672.
   PubMed Web of Science ®Google Scholar
• Perniciaro S, van der Linden M, Weinberger DM. Reemergence of invasive pneumococcal disease in Germany during the Spring and Summer of 2021. Clin Infect Dis. 2022 Sep 30;75(7):1149–1153. doi: 10.1093/cid/ciac100
   PubMed Web of Science ®Google Scholar
• Babb R, Doyle CR, Pirofski LA. Isolation and Characterization of Human Monoclonal Antibodies to Pneumococcal Capsular Polysaccharide 3. Microbiol Spectr. 2021 Dec 22;9(3):e0144621. doi: 10.1128/Spectrum.01446-21
   PubMed Web of Science ®Google Scholar
• Choi EH, Zhang F, Lu YJ, et al. Capsular polysaccharide (CPS) release by serotype 3 pneumococcal strains reduces the protective Effect of anti-type 3 CPS antibodies. Clin Vaccine Immunol. 2016 Feb;23(2):162–167.
   PubMed Web of Science ®Google Scholar
• Micoli F, Romano MR, Carboni F, et al. Strengths and weaknesses of pneumococcal conjugate vaccines. Glycoconj J. 2023 Apr;40(2):135–148.
   PubMed Web of Science ®Google Scholar
• Greenberg D, Hoover PA, Vesikari T, et al. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants. Vaccine. 2018 Oct 29;36(45):6883–6891. doi: 10.1016/j.vaccine.2018.02.113
   PubMed Web of Science ®Google Scholar
• Rupp R, Hurley D, Grayson S, et al. A dose ranging study of 2 different formulations of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants. Hum Vaccin Immunother. 2019;15(3):549–559. doi: 10.1080/21645515.2019.1568159
   PubMed Web of Science ®Google Scholar
• Hammitt LL, Quinn D, Janczewska E, et al. Immunogenicity, Safety, and Tolerability of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Immunocompetent Adults Aged 18-49 Years With or Without Risk Factors for Pneumococcal Disease: A Randomized Phase 3 Trial (PNEU-DAY). Open Forum Infect Dis. 2022 Mar;9(3):ofab605.
   PubMed Web of Science ®Google Scholar
• Hammitt LL, Quinn D, Janczewska E, et al. Phase 3 trial to evaluate the safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine 6 months later, in at-risk adults 18-49 years of age (PNEU-DAY): a subgroup analysis by baseline risk factors. Hum Vaccin Immunother. 2023 Dec 31;19(1):2177066. doi: 10.1080/21645515.2023.2177066
   PubMed Web of Science ®Google Scholar
• Kishino H, Sawata M, Igarashi R, et al. Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in Japanese adults aged >/=65 years: subgroup analysis of a randomized Phase III trial (PNEU-AGE). Jpn J Infect Dis. 2022 Nov 22;75(6):575–582. doi: 10.7883/yoken.JJID.2022.060
   PubMed Web of Science ®Google Scholar
• Mohapi L, Pinedo Y, Osiyemi O, et al. Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in adults living with HIV. AIDS. 2022 Mar 1;36(3):373–382. doi: 10.1097/QAD.0000000000003126
   PubMed Web of Science ®Google Scholar
• Platt HL, Cardona JF, Haranaka M, et al. A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE). Vaccine. 2022 Jan 3;40(1):162–172. doi: 10.1016/j.vaccine.2021.08.049
   PubMed Web of Science ®Google Scholar
• Severance R, Schwartz H, Dagan R, et al. Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, administered concomitantly with influenza vaccine in healthy adults aged >/=50 years: a randomized phase 3 trial (PNEU-FLU). Hum Vaccin Immunother. 2022 Dec 31;18(1):1–14. doi: 10.1080/21645515.2021.1976581
   PubMed Web of Science ®Google Scholar
• Song JY, Chang CJ, Andrews C, et al. Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged >/=50 years: a randomized phase III trial (PNEU-PATH). Vaccine. 2021 Oct 15;39(43):6422–6436. doi: 10.1016/j.vaccine.2021.08.038
   PubMed Web of Science ®Google Scholar
• Platt HL, Greenberg D, Tapiero B, et al. A Phase II trial of safety, tolerability and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in healthy infants. Pediatr Infect Dis J. 2020 Aug;39(8):763–770.
   PubMed Web of Science ®Google Scholar
• Administration Fa D VAXNEUVANCE™ (pneumococcal 15-valent conjugate vaccine) prescribing information. 2022 Jul. [cited 2022 Aug 10]. Available from: https://www.fda.gov/vaccines-blood-biologics/vaccines/vaxneuvance
   Google Scholar
• Agency EM. Vaxneuvance: summary of product characteristics. 2022 Nov. [cited 2023 Apr 21]. Available from: https://www.ema.europa.eu/en/documents/product-information/vaxneuvance-epar-product-information_en.pdf
   Google Scholar
• Canada G Pneumococcal vaccine: Canadian immunization guide. [cited 2023 Apr 21]. Available from: https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-16-pneumococcal-vaccine.html#a4
   Google Scholar
• Compendium EM. Vaxneuvance. Oct 2022. [cited 2023 Apr 21]. Available from: https://www.medicines.org.uk/emc/product/13754/smpc#gref
   Google Scholar
• World Health Organization. WHO Expert committee on biological standardization: seventy-fifth report. WHO Technical Report Series, No. 1043. 2022.
   Google Scholar
• Anttila M, Voutilainen M, Jantti V, et al. Contribution of serotype-specific IgG concentration, IgG subclasses and relative antibody avidity to opsonophagocytic activity against Streptococcus pneumoniae. Clin Exp Immunol. 1999 Dec;118(3):402–407.
   PubMed Web of Science ®Google Scholar
• Romero-Steiner S, Libutti D, Pais LB, et al. Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells. Clin Diagn Lab Immunol. 1997 Jul;4(4):415–422.
   PubMedGoogle Scholar
• Kieninger DM, Kueper K, Steul K, et al. Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany. Vaccine. 2010 Jun 7;28(25):4192–4203. doi: 10.1016/j.vaccine.2010.04.008
   PubMed Web of Science ®Google Scholar
• Yeh SH, Gurtman A, Hurley DC, et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers. Pediatrics. 2010 Sep;126(3):e493–505.
   PubMed Web of Science ®Google Scholar
• Nolan KM, Bonhomme ME, Schier CJ, et al. Optimization and validation of a microcolony multiplexed opsonophagocytic killing assay for 15 pneumococcal serotypes. Bioanalysis. 2020 Jul;12(14):1003–1020.
   PubMed Web of Science ®Google Scholar
• Nolan KM, Zhang Y, Antonello JM, et al. Enhanced antipneumococcal antibody electrochemiluminescence assay: validation and bridging to the WHO reference ELISA. Bioanalysis. 2020 Oct;12(19):1363–1375.
   PubMed Web of Science ®Google Scholar
• Burton RL, Nahm MH. Development and validation of a fourfold multiplexed opsonization assay (MOPA4) for pneumococcal antibodies. Clin Vaccine Immunol. 2006 Sep;13(9):1004–1009. doi: 10.1128/CVI.00112-06
   PubMed Web of Science ®Google Scholar
• Lupinacci R, Rupp R, Wittawatmongkol O, et al. A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED). Vaccine. 2023 Jan 27;41(5):1142–1152. doi: 10.1016/j.vaccine.2022.12.054
   PubMedGoogle Scholar
• Benfield T, Ramet M, Valentini P, et al. Safety, tolerability, and immunogenicity of V114 pneumococcal vaccine compared with PCV13 in a 2+1 regimen in healthy infants: a phase III study (PNEU-PED-EU-2). Vaccine. 2023 Apr 6;41(15):2456–2465. doi: 10.1016/j.vaccine.2023.02.041
   PubMed Web of Science ®Google Scholar
• Martinon-Torres F, Wysocki J, Szenborn L, et al. A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1). Vaccine. 2023 May 16;41(21):3387–3398. doi: 10.1016/j.vaccine.2023.04.036
   PubMed Web of Science ®Google Scholar
• Bili A, Dobson S, Quinones J, et al. A phase 3, multicenter, randomized, double-blind study to evaluate the interchangeability of V114, a 15-valent pneumococcal conjugate vaccine, and PCV13 with respect to safety, tolerability, and immunogenicity in healthy infants (PNEU-DIRECTION). Vaccine. 2023 Jan 16;41(3):657–665. doi: 10.1016/j.vaccine.2022.10.072
   PubMed Web of Science ®Google Scholar
• Banniettis N, Wysocki J, Szenborn L, et al. A phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of catch-up vaccination regimens of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants, children, and adolescents (PNEU-PLAN). Vaccine. 2022 Oct 19;40(44):6315–6325. doi: 10.1016/j.vaccine.2022.09.003
   PubMed Web of Science ®Google Scholar
• World Health Organization. Weekly epidemiological report, pneumococcal conjugate vaccines in infants and children under 5 years of age. WHO Wkly Epidemiol Rec. 2019;94(8):85–104.
   Google Scholar
• Melin M, Trzcinski K, Antonio M, et al. Serotype-related variation in susceptibility to complement deposition and opsonophagocytosis among clinical isolates of Streptococcus pneumoniae. Infect Immun. 2010 Dec;78(12):5252–5261.
   PubMed Web of Science ®Google Scholar
• Spijkerman J, Veenhoven RH, Wijmenga-Monsuur AJ, et al. Immunogenicity of 13-valent pneumococcal conjugate vaccine administered according to 4 different primary immunization schedules in infants: a randomized clinical trial. JAMA. 2013 Sep 4;310(9):930–937. doi: 10.1001/jama.2013.228052
   PubMed Web of Science ®Google Scholar
• Bermal N, Szenborn L, Chrobot A, et al. The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV/Hib and poliovirus vaccines: assessment of immunogenicity. Pediatr Infect Dis J. 2009 Apr;28(4 Suppl):S89–96.
   PubMed Web of Science ®Google Scholar
• Chevallier B, Vesikari T, Brzostek J, et al. Safety and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with routine childhood vaccines. Pediatr Infect Dis J. 2009 Apr;28(4 Suppl):S109–118.
   PubMed Web of Science ®Google Scholar
• Esposito S, Tansey S, Thompson A, et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers. Clin Vaccine Immunol. 2010 Jun;17(6):1017–1026.
   PubMed Web of Science ®Google Scholar
• Knuf M, Szenborn L, Moro M, et al. Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV). Pediatr Infect Dis J. 2009 Apr;28(4 Suppl):S97–S108.
   PubMed Web of Science ®Google Scholar
• Adamkiewicz TV, Sarnaik S, Buchanan GR, et al. Invasive pneumococcal infections in children with sickle cell disease in the era of penicillin prophylaxis, antibiotic resistance, and 23-valent pneumococcal polysaccharide vaccination. J Pediatr. 2003 Oct;143(4):438–444.
   PubMed Web of Science ®Google Scholar
• Al-Tawfiq JA, Rabaan AA, AlEdreesi MH. Frequency of bacteremia in patients with sickle cell disease: a longitudinal study. Ann Hematol. 2021 Jun;100(6):1411–1416. doi: 10.1007/s00277-021-04523-x
   PubMed Web of Science ®Google Scholar
• Battersby AJ, Knox-Macaulay HH, Carrol ED. Susceptibility to invasive bacterial infections in children with sickle cell disease. Pediatr Blood Cancer. 2010 Sep;55(3):401–406. doi: 10.1002/pbc.22461
   PubMed Web of Science ®Google Scholar
• Oligbu G, Fallaha M, Pay L, et al. Risk of invasive pneumococcal disease in children with sickle cell disease in the era of conjugate vaccines: a systematic review of the literature. Br J Haematol. 2019 May;185(4):743–751.
   PubMed Web of Science ®Google Scholar
• Adamkiewicz T, Thomas S, Tunali A, et al. Population-based surveillance of pneumococcal infections in children with sickle cell disease before and after Prevnar 7® and Prevnar 13® licensure: implications for expanded vaccination. Blood. 2021;138(Supplement 1):763–763. doi: 10.1182/blood-2021-154474
   Google Scholar
• Adamkiewicz TV, Silk BJ, Howgate J, et al. Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life. Pediatrics. 2008 Mar;121(3):562–569.
   PubMed Web of Science ®Google Scholar
• De Montalembert M, Abboud MR, Fiquet A, et al. 13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): results of a phase 3 study. Pediatr Blood Cancer. 2015 Aug;62(8):1427–1436.
   PubMed Web of Science ®Google Scholar
• McCavit TL, Xuan L, Zhang S, et al. Hospitalization for invasive pneumococcal disease in a national sample of children with sickle cell disease before and after PCV7 licensure. Pediatr Blood Cancer. 2012 Jun;58(6):945–949.
   PubMed Web of Science ®Google Scholar
• Nuorti JP, Whitney CG, Centers for Disease C, et al. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on immunization Practices (ACIP). MMWR Recomm Rep. 2010 Dec 10;59(RR–11):1–18.
   PubMedGoogle Scholar
• Quinn CT, Wiedmann RT, Jarovsky D, et al. Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in children with SCD: a V114-023 (PNEU-SICKLE) study. Blood Adv. 2023 Feb 14;7(3):414–421. doi: 10.1182/bloodadvances.2022008037
   PubMed Web of Science ®Google Scholar
• Wilck M, Barnabas S, Chokephaibulkit K, et al. A phase 3 study of safety and immunogenicity of V114, a 15-valent PCV, followed by PPSV23, in children living with HIV. AIDS. 2023 Mar 20;37(8):1227–1237. doi: 10.1097/QAD.0000000000003551
   PubMed Web of Science ®Google Scholar
• Madhi SA, Petersen K, Madhi A, et al. Increased disease burden and antibiotic resistance of bacteria causing severe community-acquired lower respiratory tract infections in human immunodeficiency virus type 1-infected children. Clin Infect Dis. 2000 Jul;31(1):170–176.
   PubMed Web of Science ®Google Scholar
• Meiring S, Cohen C, Quan V, et al. HIV infection and the epidemiology of invasive pneumococcal disease (IPD) in South African adults and older children prior to the introduction of a pneumococcal conjugate vaccine (PCV). PLoS One. 2016;11(2):e0149104. doi: 10.1371/journal.pone.0149104
   PubMed Web of Science ®Google Scholar
• Nunes MC, von Gottberg A, de Gouveia L, et al. The impact of antiretroviral treatment on the burden of invasive pneumococcal disease in South African children: a time series analysis. AIDS. 2011 Feb 20;25(4):453–462. doi: 10.1097/QAD.0b013e328341b7f1
   PubMed Web of Science ®Google Scholar
• Kent A, Makwana A, Sheppard CL, et al. Invasive pneumococcal disease in UK children <1 year of age in the post-13-valent pneumococcal conjugate vaccine era: what are the risks Now? Clin Infect Dis. 2019 Jun 18;69(1):84–90. doi: 10.1093/cid/ciy842
   PubMed Web of Science ®Google Scholar